research
An HIV Regimen Matched Suppression With Less Weight Gain
A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.
Summary
A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.
The Opti-DOR trial in rural KwaZulu-Natal and urban Gauteng compared tenofovir-lamivudine-doravirine with the country's standard tenofovir-lamivudine-dolutegravir regimen. Researchers report that doravirine was noninferior for viral suppression and was associated with less weight gain and better lipid measures. The result offers another treatment option; individual prescribing still depends on clinical guidance and access.
Why it matters
A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.
Limits and context
No additional limitation was separately recorded.
Key claims
A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.
Evidence: source-2026-08-01-016
Sources
- Wits University via Newswise: Opti-DOR HIV trialUniversity of the Witwatersrand via Newswise · official announcement
Corrections
No corrections have been recorded for this story.